Milicić-Juhas Valerija, Perić Marija, Pajtler Marija, Prvulović Ivana, Curzik Darko
Department of Clinical Cytology, University Hospital Center Osijek, Osijek, Croatia.
Coll Antropol. 2010 Mar;34(1):69-74.
The aim of this study was to evaluate medical and economic justification of vaginal smears as a part of primary screening for cervical carcinoma and its precursors. Study included 245.048 participants whose VCE (vaginal, cervical, endocervical) smears were examined at Department of clinical cytology of University Hospital Center Osijek from 2003 till 2008. There were 12.639 (5.2%) abnormal findings, and they were divided into three groups: abnormal cells found only in vaginal smear (V), abnormal cells found in vaginal and in at least one other smear (V+) and abnormal cells not found in vaginal smear (C/E). These three groups were analysed in respect to cytological differential diagnosis and age of participants. It was estimated how many women could be additionally included in the screening, if vaginal smear would be included in the Pap test only after 50 years of age. In 6.9% of cytologically diagnosed lesions abnormal cells were found exclusively in vaginal smears (0.35% of all findings). As for squamous cell lesions, 91.2% were mild lesions (ASC and LSIL). Invasive squamous cell carcinoma was not diagnosed exclusively by vaginal smear in either woman under 50 years of age, while in women over 50 years of age it was diagnosed in 2.3% of cases. Exclusively by vaginal smear was diagnosed 3.9% of all AGC and 6.3% of adenocarcinoma, while in 85.0% of glandular epithelium lesions abnormal cells were not found in vaginal smears. Two thirds of adenocarcinoma diagnosed exclusively by vaginal smears were endometrial adenocarcinoma, but that is only 10.3% of all endometrial carcinoma diagnosed by Pap test. Obtained results show that taking of vaginal smears along with cervical and endocervical smears as a part of primary screening for cervical carcinoma and its precursors in women under 50 years of age is not justifiable, since vaginal smear only has a role in detection of endometrial carcinoma that are extremely rare in younger age groups. If vaginal smear would be taken only in women over 50 years of age, additional 37.7% of women under 50, or 25.1% women over 50 years of age could be included in the screening.
本研究的目的是评估阴道涂片作为宫颈癌及其癌前病变初筛一部分的医学和经济合理性。该研究纳入了245,048名参与者,他们于2003年至2008年在奥西耶克大学医院中心临床细胞学部门接受了阴道、宫颈、宫颈管涂片(VCE)检查。共有12,639例(5.2%)异常结果,这些结果被分为三组:仅在阴道涂片中发现异常细胞(V)、在阴道及至少一份其他涂片中发现异常细胞(V+)以及未在阴道涂片中发现异常细胞(C/E)。对这三组进行了细胞学鉴别诊断和参与者年龄方面的分析。估计了如果仅在50岁以后将阴道涂片纳入巴氏试验,筛查中可以额外纳入多少女性。在6.9%的经细胞学诊断的病变中,异常细胞仅在阴道涂片中发现(占所有结果的0.35%)。对于鳞状细胞病变,91.2%为轻度病变(非典型鳞状细胞和低度鳞状上皮内病变)。50岁以下女性中,没有一例浸润性鳞状细胞癌仅通过阴道涂片诊断出来,而50岁以上女性中,有2.3%的病例通过阴道涂片诊断出来。所有非典型腺细胞中有3.9%以及腺癌中有6.3%仅通过阴道涂片诊断出来,而在85.0%的腺上皮病变中,阴道涂片中未发现异常细胞。仅通过阴道涂片诊断出的腺癌中有三分之二为子宫内膜腺癌,但这仅占通过巴氏试验诊断出的所有子宫内膜癌的10.3%。所得结果表明,在50岁以下女性中,将阴道涂片与宫颈和宫颈管涂片一起作为宫颈癌及其癌前病变初筛的一部分是不合理的,因为阴道涂片仅在检测子宫内膜癌方面有作用,而子宫内膜癌在年轻年龄组中极为罕见。如果仅对50岁以上女性进行阴道涂片检查,50岁以下女性中可额外有37.7%或50岁以上女性中25.1%可纳入筛查。